Breakthrough Hormone May Help Tackle Obesity
Researchers at the University of Oklahoma have made an exciting discovery related to weight loss. A new hormone called FGF21 (fibroblast growth factor 21) has shown potential in reversing obesity in mice, according to a study published in Cell Reports.
This hormone appears to communicate with a particular area in the brain responsible for managing metabolism and appetite. Interestingly, it targets the same region that is affected by popular weight-loss medications known as GLP-1 drugs.
FGF21 is already being explored in the development of treatments for a liver condition known as metabolic dysfunction-associated steatohepatitis (MASH), a type of fatty liver disease. Dr. Matthew Potthoff, the lead author of the study and a professor at the OU College of Medicine, mentioned that they found FGF21 sends signals to a part of the brain located in the lower back. This came as a surprise, as researchers initially thought it would signal to the hypothalamus, which is widely recognized for its role in regulating body weight.
The interaction between FGF21 and the brain seems to enhance metabolic processes, which might help in weight loss. However, the study’s findings also indicate that this process may come with some unwanted side effects, such as digestive issues and potential bone density loss.
Dr. Potthoff aims for future FGF21 therapies to be more targeted, minimizing negative effects. He expressed hope that identifying the specific brain signals could lead to better treatments.
While FGF21 and GLP-1 both act on the same brain area, they work in different ways. GLP-1 suppresses appetite, while FGF21 boosts metabolism, increasing energy expenditure.
Dr. Peter Balazs, a specialist in hormone and weight management, pointed out that this research offers a new pathway for weight management by possibly focusing on metabolic rates rather than just calorie counting. However, he also cautioned that this study was conducted on mice, which may not fully represent human obesity.
FGF21 behaves differently in humans compared to mice; for instance, people with obesity tend to have elevated levels of this hormone. Concerns remain about the potential side effects of FGF21 treatments, especially since obesity can already heighten fracture risks.
Earlier trials on humans have indicated modest weight loss of about 5% to 8%. This is notably less than the average 15% weight loss seen with GLP-1 treatments. There are also questions about the long-term effects of FGF21 and whether the body might become less responsive to it over time.
Overall, while this study offers a promising start towards new obesity treatments, thorough safety trials and additional research will be essential for confirming its effectiveness in humans.
